Dopamine, endocannabinoids and their interaction in fear extinction and negative affect in PTSD.
Comorbidity
Dopamine
Endocannabinoids
PTSD
Posttraumatic stress disorder
Journal
Progress in neuro-psychopharmacology & biological psychiatry
ISSN: 1878-4216
Titre abrégé: Prog Neuropsychopharmacol Biol Psychiatry
Pays: England
ID NLM: 8211617
Informations de publication
Date de publication:
08 03 2021
08 03 2021
Historique:
received:
19
05
2020
revised:
03
09
2020
accepted:
22
09
2020
pubmed:
30
9
2020
medline:
31
12
2021
entrez:
29
9
2020
Statut:
ppublish
Résumé
There currently exist few frameworks for common neurobiology between reexperiencing and negative cognitions and mood symptoms of PTSD. Adopting a dopaminergic framework for PTSD unites many aspects of unique symptom clusters, and this approach also links PTSD symptomology to common comorbidities with a common neurobiological deficiency. Here we review the dopamine literature and incorporate it with a growing field of research that describes both the contribution of endocannabinoids to fear extinction and PTSD, as well as the interactions between dopaminergic and endocannabinoid systems underlying this disorder. Based on current evidence, we outline an early, preliminary model that links re-experiencing and negative cognitions and mood in PTSD by invoking the interaction between endocannabinoid and dopaminergic signalling in the brain. These interactions between PTSD, dopamine and endocannabinoids may have implications for future therapies for treatment-resistant and comorbid PTSD patients.
Identifiants
pubmed: 32991952
pii: S0278-5846(20)30434-6
doi: 10.1016/j.pnpbp.2020.110118
pii:
doi:
Substances chimiques
Endocannabinoids
0
Dopamine
VTD58H1Z2X
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
110118Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.